KPV: What the Research Shows
For laboratory and research use only. This article summarises published scientific research on KPV. Neurovia’s KPV is not intended for human consumption. See our disclaimer.
KPV: What the Research Shows
KPV peptide is a naturally occurring tripeptide — the C-terminal fragment of alpha-MSH (alpha-Melanocyte Stimulating Hormone) — that has attracted growing research interest as a potent anti-inflammatory research compound with a notably small molecular size. At just three amino acids, KPV is one of the smallest biologically active peptides in the research literature, a property that influences its studied stability and oral bioavailability characteristics.
This article provides an evidence-based overview of KPV: its molecular identity, its relationship to alpha-MSH, the published research landscape, and supply format for laboratory use.
What Is KPV peptide?
KPV is a tripeptide with the sequence Lys-Pro-Val — the C-terminal three amino acids (positions 11–13) of alpha-MSH. Alpha-MSH itself is a 13-amino acid peptide derived from POMC (pro-opiomelanocortin) and is the endogenous ligand for melanocortin receptors.
Molecular profile:
- Sequence: Lys-Pro-Val
- Length: 3 amino acids
- Molecular weight: ~341 Da
- Origin: C-terminal fragment of alpha-MSH (α-MSH 11–13)
- CAS Number: 69-89-6 (free acid form)
The relevance of KPV’s small size is significant: most peptides above a certain molecular weight have poor oral bioavailability due to enzymatic degradation in the GI tract and limited intestinal absorption. KPV’s tripeptide structure makes it substantially more resistant to peptidase degradation than larger peptides, and published research has examined its oral bioavailability characteristics in preclinical models.
The Alpha-MSH Connection
To understand KPV’s research context, it is helpful to understand its parent peptide. Alpha-MSH (α-MSH) activates melanocortin receptors — particularly MC1R, MC3R, and MC4R — with published research establishing its role in:
- Pigmentation (MC1R-mediated melanogenesis)
- Energy regulation and appetite (MC3R/MC4R)
- Anti-inflammatory signalling (multiple receptor subtypes, particularly MC1R)
The anti-inflammatory activity of alpha-MSH has a well-established published literature, with research demonstrating its ability to downregulate pro-inflammatory cytokine production and NFκB signalling in cell culture and animal models.
KPV, as the C-terminal fragment of alpha-MSH, has been studied as a minimal anti-inflammatory sequence — retaining anti-inflammatory activity at a fraction of the molecular weight of the parent peptide.
The Published Research Landscape
Anti-Inflammatory Research
The primary published research focus for KPV is its anti-inflammatory activity in cell culture and preclinical animal models. Published studies have examined KPV’s effects on:
NFκB signalling — Multiple published studies have examined KPV’s interactions with the NFκB inflammatory signalling pathway in cell culture models. NFκB is a master regulator of inflammatory gene expression, and its inhibition is a common mechanism studied in anti-inflammatory research contexts.
Pro-inflammatory cytokine modulation — Published research has examined KPV’s studied effects on IL-1β, TNF-α, and IL-6 production in cell culture models stimulated with inflammatory agents.
Macrophage research — Some published studies have specifically examined KPV’s interactions with macrophage inflammatory responses — relevant to its studied anti-inflammatory mechanism.
Gastrointestinal Research
A notable body of published research has examined KPV specifically in gastrointestinal inflammatory contexts — making it one of the more relevant peptides for gut biology research.
Published preclinical studies have examined KPV in colitis models in rodents, with work examining its studied effects on intestinal inflammatory markers, gut barrier integrity, and colon tissue histology in animal models. This research is published in gastroenterology and inflammation journals and represents one of the more focused preclinical research areas for KPV.
The gastrointestinal research context is also relevant to KPV’s oral bioavailability characteristics — its small size and stability make it potentially more suitable for oral research administration than larger peptides, and published research has examined this in preclinical models.
Skin Research
Given the peptide’s alpha-MSH origin and MC1R’s established role in skin biology, some published research has examined KPV in dermatological contexts — skin inflammation, wound healing, and UV response pathways in cell culture and animal models.
Melanocortin Receptor Research Context
KPV’s relationship to the melanocortin system is relevant to understanding its research profile. Published research has not definitively established that its anti-inflammatory effects are purely receptor-mediated — some studies have proposed receptor-independent mechanisms contributing to its observed anti-inflammatory activity in cell culture.
This distinguishes KPV’s research profile from larger melanocortin agonists like PT-141 and Melanotan 2, which have more clearly defined receptor activity profiles. KPV’s mechanism is an area of active investigation in the published literature.
KPV in Research Blends
KPV is frequently combined with BPC-157 in research blend formats due to the complementary nature of their studied research profiles — BPC-157’s gastrointestinal and tissue repair research context and KPV’s gut inflammatory research context. Neurovia supplies several BPC-157/KPV combination formats in the BPC Wolverine product range.
Supply Format for Research
Neurovia supplies KPV in the following research formats:
- KPV 10mg — lyophilised vial
- BPC Wolverine + KPV blends — combination vials with BPC-157
All supplied at 99% purity, third-party tested, with Certificate of Analysis available.
Further reading: peer-reviewed research on KPV peptide (PubMed).
Frequently Asked Questions
What is KPV peptide?
KPV is a tripeptide (Lys-Pro-Val) corresponding to the C-terminal three amino acids of alpha-MSH. It has been studied in anti-inflammatory, gastrointestinal, and skin biology research contexts in cell culture and preclinical animal models.
What is KPV research peptide used for?
KPV is used in laboratory research investigating anti-inflammatory mechanisms, gastrointestinal inflammatory pathways, NFκB signalling, and melanocortin system biology. Its small size (3 amino acids) makes it relevant to oral bioavailability research as well.
What are KPV peptide studies?
Published KPV studies primarily cover anti-inflammatory cell culture research (NFκB, cytokine modulation), gastrointestinal colitis models in rodents, skin biology, and alpha-MSH fragment activity research. The gastrointestinal research context is among the more developed published areas.
What is the connection between KPV and alpha-MSH?
KPV is the C-terminal tripeptide fragment of alpha-MSH (positions 11–13). Alpha-MSH is an endogenous melanocortin peptide with established anti-inflammatory activity in the published literature. KPV has been studied as a minimal active sequence retaining anti-inflammatory properties at a much smaller molecular size.
Why is KPV combined with BPC-157 in research?
KPV and BPC-157 have complementary research profiles — KPV’s anti-inflammatory gastrointestinal research context and BPC-157’s gastrointestinal and tissue repair research context make them relevant to study in combination. Published and referenced research has examined this combination in gut-related preclinical contexts.
How is KPV supplied for research?
KPV is available as a lyophilised powder (10mg vial) and in BPC Wolverine + KPV combination vials. Neurovia supplies KPV at 99% purity with third-party Certificate of Analysis.
This article summarises published peer-reviewed research on KPV and is provided for informational purposes only. Neurovia’s KPV is supplied for laboratory research use only and is not intended for human consumption. Full disclaimer →
Related Products & Research